Retatrutide clinical trials: what the data actually shows

Last updated 2026-07-25

What do the retatrutide clinical trials actually show so far?

The headline number comes from a phase 2 obesity trial published in the New England Journal of Medicine: at the 12 mg dose, participants lost a mean of 24.2 percent of body weight at 48 weeks, compared to 2.1 percent in the placebo group ^[1]. That's a big gap, and it's the number every headline about retatrutide is built on. The trial is registered publicly as NCT04881760, titled "A Study of LY3437943 in Participants Who Have Obesity or Are Overweight," and LY3437943 is retatrutide's development code before it had a public name ^[2]. The trial dosed participants with weekly subcutaneous injection, the same delivery method used for semaglutide and tirzepatide ^[2]. It tested multiple dose arms, more than 12 mg, and the ClinicalTrials.gov record lists the full comparator and dosing structure if you want to check the source directly ^[2]. Beyond the phase 2 obesity data, retatrutide has moved into registered type 2 diabetes trials as well, so the evidence base isn't limited to weight loss alone ^[3]. It has also advanced into later-phase trials. Two separate registrations, NCT05929066 and NCT05882045, give independent public records of the dosing and design being studied at this later stage ^{[4] [5]}. None of this changes the drug's regulatory status. Trial data, even strong trial data, is not the same thing as an approved medicine you can be prescribed.

Is retatrutide FDA approved?

No. A direct query of Drugs@FDA, the FDA's own database of approved drug products, for the generic name retatrutide returns no approved product ^[1]. There is no brand name, no NDA number, nothing. If a website or vendor implies otherwise, that claim is false on its face and checkable in about thirty seconds using FDA's public database. This matters because trial results and approval are two different things entirely. A drug can post remarkable phase 2 numbers and still be years from a decision, or never reach one. Under 21 U.S.C. 355, a new drug cannot legally enter interstate commerce without an approved application . That's the statute doing the work here, not FDA caution or bureaucracy for its own sake. Until retatrutide clears that bar, it stays in the trial-only category, full stop.

Can a pharmacy legally compound retatrutide?

No, and this is worth walking through carefully because it's the part vendors tend to obscure. Section 503A of the Food, Drug and Cosmetic Act allows compounding from a bulk substance only through a specific cascade, in this order: the substance must comply with a USP or NF monograph if one exists; if no monograph exists, it must be a component of an FDA-approved drug; only if neither of those applies can it come from the 503A Bulks List ^[6]. Retatrutide fails all three tests. There's no USP monograph for it. There's no FDA-approved drug containing it (see above). And it is not on the 503A Bulks List. That list, codified at 21 CFR 216.23, contains exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide ^[6]. No peptide of any kind appears on it, retatrutide included. There's a separate, independent requirement too. Even setting the ingredient cascade aside, 503A requires that any bulk drug substance come from an establishment registered under FD&C Act section 510, accompanied by a valid certificate of analysis ^[7]. Research-use-only material from an unregistered supplier fails this test regardless of anything else about the substance. So retatrutide fails on two independent legal grounds, not one. For outsourcing facilities operating under 503B rather than 503A, the relevant list is 21 CFR 216.24, and retatrutide is absent from that one too ^[8]. If you're trying to understand how these rules apply more broadly to retatrutide peptide sourcing, this cascade is the mechanism that makes it unlawful, not a vague policy stance.

Was retatrutide considered for the 503A Bulks List recently?

No, and this is a common point of confusion. FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026, to consider seven peptides for possible inclusion on the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax, and epitalon ^[9]. Retatrutide was not among them. It has never been nominated for that list at all ^[9]. Even if it had been, and even if the committee had voted favorably on those seven, that alone changes nothing legally. FDA advisory committee recommendations are non-binding. Adding any substance to the 503A Bulks List requires full notice-and-comment rulemaking, a formal regulatory process with public comment periods and Federal Register publication, not a committee vote ^[9]. So the existence of that meeting doesn't create a pathway for the seven peptides discussed, and it says nothing at all about retatrutide, which wasn't part of the conversation.

How is retatrutide different from semaglutide and tirzepatide?

Mechanistically, retatrutide is a triple agonist: it acts at the GIP, GLP-1, and glucagon receptors simultaneously ^[1]. Semaglutide (marketed as Ozempic and Wegovy) acts on the GLP-1 receptor alone ^[2]. Tirzepatide (marketed as Mounjaro and Zepbound) hits two receptors, GIP and GLP-1 ^[2]. Retatrutide adds a third mechanism, the glucagon receptor, which is the theoretical basis for its larger weight-loss signal in trials. Here's a quick comparison of where each stands: | Compound | Receptors targeted | Approved brand names | FDA status |

Why can't I just get retatrutide from a research chemical site?

You can find it for sale. That doesn't make the sale legal, and it definitely doesn't make it safe. Sites selling retatrutide almost always carry a "research use only" or "not for human consumption" disclaimer. FDA has been explicit that this disclaimer does not change how a product is legally classified. In a warning letter to Gram Peptides dated March 31, 2026, FDA wrote that despite research-use labeling, "evidence from the company's website established that its products were intended to be drugs for human use" ^[11], and the letter specifically cited retatrutide marketed on that site. The legal basis for this is 21 CFR 201.128, which grounds a product's intended use in labeling claims, advertising, and statements made by the seller, not in a disclaimer buried in the fine print ^[12]. If a site's marketing copy talks about weight loss, dosing schedules, or therapeutic benefits, that language is what determines intended use in FDA's eyes, and it makes the product an unapproved new drug being illegally marketed for human use. Separately, FDA maintains a policy on personal importation of unapproved drugs for anyone considering ordering investigational compounds from overseas suppliers ^[13]. That policy exists precisely because this is a common workaround people try, and it doesn't create a loophole. The bottom line: a vial labeled "not for human consumption" sitting next to marketing copy about fat loss is not a gray area FDA has left open. It's a warning-letter-shaped target.

What doses were used in the retatrutide trials, and does that mean I could self-dose the same way?

The phase 2 trial tested multiple dose arms delivered by weekly subcutaneous injection, with the 12 mg arm producing the 24.2 percent mean weight loss figure at 48 weeks ^{[1] [2]}. Those are the numbers reported in the trial, administered under clinical supervision, with monitoring, lab work, and a controlled manufacturing chain behind every dose. That is not a protocol you can replicate safely at home with a vial from an unregulated seller. No clinician in the United States can lawfully prescribe retatrutide outside of a registered trial, because there's no approved product and no compounding pathway, as covered above ^[6] . What a trial reports as a dose used under a specific monitored protocol is completely different from an instruction to self-administer an unregulated substance of unknown purity. If you're seeing dosing numbers referenced anywhere outside a clinical trial context, including on our own retatrutide dosage chart or dosage calculator pages, treat those as reporting on trial data, not instructions for you to follow independently.

What are the known side effects and safety signals so far?

Trial-reported safety data exists, but it comes from a controlled, monitored, relatively short-duration research setting, not from years of real-world prescribing the way approved drugs have. GLP-1/GIP class drugs commonly produce gastrointestinal side effects (nausea, vomiting, diarrhea), and there's no reason to expect a triple agonist would be exempt from that pattern, arguably more so given the added mechanism. For the specific breakdown of adverse events reported in the retatrutide trials, see our dedicated retatrutide side effects page. The more urgent safety issue for anyone considering an unregulated source isn't the drug's pharmacology at all. It's supply chain integrity. Material from an unregistered supplier has no certificate of analysis and no FDA oversight of manufacturing conditions ^[7]. You have no reliable way to know what's actually in the vial, at what concentration, or whether it's sterile. That risk exists independent of whatever retatrutide itself does in the body, and it's arguably the bigger danger for anyone tempted to source it outside a trial.

If retatrutide isn't available, what are my actual options right now?

If you're dealing with obesity or a related metabolic condition and looking at retatrutide headlines because you want results like the 24.2 percent figure, the realistic path today runs through drugs that are actually approved. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are both FDA-approved with published safety data behind them ^[2]. Orforglipron (Foundayo) adds an oral option, approved across six strengths ^[10]. None of these match retatrutide's exact numbers in trials, since it hasn't been compared head-to-head against them in a completed approved-drug context. But they are legal, prescribable, and monitored by a physician, which counts for a lot. NIDDK, the federal government's authority on the topic, publishes evidence-based guidance on weight management that's a useful neutral starting point while you wait for any newer drug to clear the approval bar . That's not a consolation prize. It's the actual state of the science and the law as of today. A clinician working from an approved drug and real monitoring data will always be a better bet than an unregulated vial promising the same headline number you saw in a trial writeup.

Could retatrutide still get FDA approved, and when?

It's plausible, but nobody outside the sponsor and FDA has a reliable timeline, and anyone giving you a specific approval date is guessing. What we do know: retatrutide has moved into later-phase registered trials, evidenced by two independent ClinicalTrials.gov records, NCT05929066 and NCT05882045, that list enrollment criteria, comparators, and endpoints currently being tested ^{[4] [5]}. Progressing to later-phase trials is a meaningful step, phase 2 results alone don't get a drug approved, and plenty of promising phase 2 compounds never clear phase 3 or the FDA review that follows. The honest answer is: keep watching Drugs@FDA yourself if you want the real-time answer, because that's the same source anyone reporting on this uses ^[1]. There's no shortcut, and no credible source can currently tell you an exact approval year.

Frequently asked questions

Is retatrutide FDA approved for weight loss or diabetes?

No. A direct search of Drugs@FDA, FDA's official database of approved drug products, for "retatrutide" returns no approved product under any brand name. It remains investigational, tested only in registered clinical trials, with no approved indication for obesity, overweight, or type 2 diabetes as of this writing.

What weight loss results has retatrutide shown in trials?

In the phase 2 obesity trial (NCT04881760), participants at the 12 mg dose lost a mean of 24.2 percent of body weight at 48 weeks, compared to 2.1 percent in the placebo group, dosed by weekly subcutaneous injection. This is the largest published mean weight-loss figure among incretin-based obesity drugs to date.

Can a compounding pharmacy legally make retatrutide?

No. Section 503A requires a bulk substance to match a USP/NF monograph, or be a component of an FDA-approved drug, or appear on the 503A Bulks List. Retatrutide meets none of these. The Bulks List (21 CFR 216.23) contains only six substances, no peptides, and retatrutide has never been nominated for it.

Is retatrutide on the FDA's 503A Bulks List?

No. The complete final 503A Bulks List, codified at 21 CFR 216.23, contains exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide. Retatrutide is not one of them, and no peptide of any kind is currently listed.

Does a "research use only" label make retatrutide sales legal?

No. FDA has stated that such disclaimers do not defeat drug status if a seller's website carries therapeutic or structure-function claims. A March 2026 warning letter to Gram Peptides cited retatrutide specifically, noting the site's marketing established intended use as a drug for humans regardless of the disclaimer used.

How is retatrutide different from tirzepatide and semaglutide?

Retatrutide is a triple agonist, acting on GIP, GLP-1, and glucagon receptors. Tirzepatide (Mounjaro, Zepbound) acts on two receptors, GIP and GLP-1. Semaglutide (Ozempic, Wegovy) acts on GLP-1 alone. The added glucagon mechanism in retatrutide is the proposed reason for its larger weight-loss signal in early trials.

Was retatrutide part of the 2026 FDA compounding advisory meeting?

No. That meeting, held July 23-24, 2026, considered seven other peptides (BPC-157, KPV, TB-500, MOTS-c, emideltide/DSIP, semax, epitalon) for possible 503A Bulks List inclusion. Retatrutide was not discussed and has never been formally nominated for that list.

What clinical trials is retatrutide currently registered in?

Key public registrations include NCT04881760 (phase 2 obesity trial), plus later-phase trials NCT05929066 and NCT05882045. Retatrutide has also been studied in registered type 2 diabetes trials. Each ClinicalTrials.gov record lists specific dose arms, comparators, and enrollment criteria you can review directly.

Are there any approved alternatives to retatrutide right now?

Yes. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved with published safety data. Orforglipron, an oral GLP-1 agonist, is approved as Foundayo (NDA 220934) in six strengths. None match retatrutide's trial numbers exactly, but all are legal and prescribable today.

Is it legal to import retatrutide personally for my own use?

FDA publishes a specific policy on personal importation of unapproved drugs, which governs anyone considering ordering investigational compounds like retatrutide from overseas. The policy does not create a loophole for unapproved drugs; retatrutide remains an unapproved new drug under 21 U.S.C. 355 regardless of the ordering method.

What doses of retatrutide were used in clinical trials?

The phase 2 trial tested multiple weekly subcutaneous dose arms, with the 12 mg dose producing a mean 24.2 percent weight reduction at 48 weeks. These figures describe supervised trial dosing under monitored conditions, not a protocol suitable or legal for unsupervised self-administration outside a trial.

Why do vendors sell retatrutide if it's not approved?

Some vendors sell it labeled "research use only," a disclaimer FDA has repeatedly ruled does not exempt a product from drug regulation if the site's marketing implies human use. FDA has issued warning letters over exactly this practice, and getting retatrutide from such sources carries both legal and safety risk given the lack of manufacturing oversight.

Sources

1. FDA, Drugs@FDA database / Jastreboff AM et al., NEJM 2023: 24.2% mean weight reduction at 12mg dose vs 2.1% placebo at 48 weeks; triple agonist mechanism at GIP, GLP-1, glucagon receptors
2. ClinicalTrials.gov NCT04881760: Phase 2 obesity trial registration, dose arms, weekly subcutaneous route, LY3437943 development code
3. 21 CFR 216.23, eCFR: The 503A Bulks List contains exactly six substances, no peptides, retatrutide absent
4. 21 U.S.C. 353a(b)(1)(A)(ii)-(iii): 503A requires bulk substances from FDA-registered establishments with a valid certificate of analysis
5. Drugs@FDA, NDA 220934 (Foundayo/orforglipron): Orforglipron approved as Foundayo in six strengths from 0.8mg to 17.2mg
6. 21 CFR 201.128: Intended use is grounded in labeling claims, advertising, and seller statements, not disclaimers
7. Federal Register, Docket FDA-2025-N-6895: July 2026 advisory committee considered seven peptides, not retatrutide, and committee votes are non-binding
8. ClinicalTrials.gov NCT05929066: Later-phase retatrutide trial registration with enrollment criteria and endpoints
9. ClinicalTrials.gov NCT05882045: Second later-phase retatrutide trial registration
10. Drugs@FDA, FDA-approved drug products database: Semaglutide approved as Ozempic/Wegovy and tirzepatide as Mounjaro/Zepbound; retatrutide has no approved product
11. 21 CFR 216.24: The separate 503B bulks list also does not include retatrutide
12. FDA, Personal Importation: FDA policy on personal importation of unapproved drugs applies to anyone ordering retatrutide from overseas
13. 21 U.S.C. 355: New drugs cannot enter interstate commerce without an approved application
14. NIDDK, Weight Management: Federal guidance on evidence-based weight management as a neutral reference point